Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bepafant SCHEMBL29658830 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Bepafant SCHEMBL29603620 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Bepafant SCHEMBL9746762 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Bepafant SCHEMBL10435458 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442169 | 0.93 | PTAFR (0.87) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL29603717 | 0.93 | PTAFR (0.87) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442268 | 0.92 | PTAFR (0.85) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442309 | 0.92 | PTAFR (0.84) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL29602738 | 0.92 | PTAFR (0.84) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442260 | 0.91 | PTAFR (0.84) | PTAFRCYP3A4ALOX15OPRK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2021-04-01 | — | — | US | claimed |
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | POLYMEDIX, INC. | 2019-10-17 | — | — | US | claimed |
| US-20160228435-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2016-08-11 | — | — | US | claimed |
| US-9192623-B2 | Arylamide compounds and compositions and uses thereof | CELLCEUTIX CORPORATION (US) | 2015-11-24 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2114395-B1 | OPHTHALMIC AND OTIC COMPOSITIONS OF FACIALLY AMPHIPHILIC POLYMERS AND OLIGOMERS AND USES THEREOF | CELLCEUTIX CORP (US) | 2015-03-04 | — | — | EP | claimed |
| CN-102600163-B | Ophthalmic and otic compositions of facially amphiphilic polymers and oligomers and uses thereof | POLYMEDIX INC. (US) | 2014-10-01 | — | — | CN | claimed |
| US-20130065818-A1 | Arylamide Compounds And Compositions And Uses Thereof | POLYMEDIX (US) | 2013-03-14 | — | — | US | claimed |
| US-20120093759-A1 | Medical Devices, Wound Dressings, and Methods for Dressing Wounds | VACHON DAVID J (US) | 2012-04-19 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-6551584-B2 | Oxazolidinone antibacterial drug, for example linezolid, in a concentration effective for treatment or prophylaxis of a grampositive bacterial infection of an eye | PHARMACIA & UPJOHN COMPANY | 2003-04-22 | — | — | US | claimed |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002030395-A1 | TOPICAL ANTIBIOTIC COMPOSITION FOR TREATMENT OF EYE INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | claimed |
| WO-2002005815-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | claimed |
| EP-0551860-A1 | PAF-antagonists as medicaments for the treatment of dysmenorrhea | BOEHRINGER INGELHEIM KG (DE) | 1993-07-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
| US-20130065818-A1 | Arylamide Compounds And Compositions And Uses Thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | CUTA, DEK, LPXN | PTAFR 3892/4885CYP3A4 1733/4885ALOX15 2793/4885 |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PTGS2, PTGES2, PTGS1 | PTAFR 739/4885CYP3A4 947/4885ALOX15 43/4885 |
| US-20160228435-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | PTAFR 3487/4885CYP3A4 3210/4885ALOX15 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.